
    
      This is a randomised, double-blind, placebo-controlled study of the safety, tolerability and
      pharmacokinetics of single ascending doses of MEDI0618 in healthy male and female volunteers.

      This study will include 9 planned cohorts; 8 cohorts will receive single ascending doses of
      MEDI0618 or placebo by intravenous administration, 1 cohort will receive MEDI0618 or placebo
      by subcutaneous administration.All subjects will undergo scheduled safety, tolerability,
      pharmacokinetic and immunogenicity assessments while in the clinical unit and as outpatients
      to the end of the follow-up period.
    
  